Haleon offers a financially sound consumer health franchise with strong margins and a favorable risk/reward setup, but a death cross and sustained negative price momentum block near-term entry; the thesis requires a technical reversal before the asymmetric upside becomes actionable.
Thesis pillars
- Quality Margins Piotroski→Stable
- Death Cross Price Momentum↑Improving
- Asymmetric Upside Risk Reward→Stable
- +1 more pillar — see the Why tab for full reasoning
Haleon plc (HLN) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $9.22, but acceptable to hold if already in. Reason: Weak growth.
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such... Read more
Hold if already holding. Not a fresh buy at $9.22, but acceptable to hold if already in. Reason: Weak growth. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.1/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 153d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent developments
updated 2026-09-25Recent Developments — Haleon plc
Latest news
- NEWS Haleon PLC (HLN) Institutional Confidence - TradingKey — TradingKey positive
- NEWS What Is Pulling Healthcare Stocks Into Focus Around Haleon (LSE:HLN)? - Kalkine Media — Kalkine Media neutral
- NEWS Haleon tops FTSE 100 as buyback cuts voting shares ahead of H1 earnings - Bez Kabli — Bez Kabli positive
- NEWS Haleon Plc and Microsoft Corporation Enter Five-Year Collaboration to Accelerate AI-Powered Transformation - marketscree — marketscreener.com positive
- NEWS Haleon Sees Volume Recovery From North America, and Margins Continue to Improve - Morningstar — Morningstar positive
Generated 2026-09-25T23:46:58Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $9.22, but acceptable to hold if already in. Reason: Weak growth. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $10.38 (+12.6%), stop $8.83 (−4.4%), A.R:R 2.5:1. Score 5.1/10, moderate confidence.
Take-profit target: $10.38 (+12.6% upside). Target $10.38 (+12.6%), stop $8.83 (−4.4%), A.R:R 2.5:1. Stop-loss: $8.83.
Weak growth.
Haleon plc trades at a P/E of 19.0 (forward 14.7). TrendMatrix value score: 5.9/10. Verdict: Hold.
26 analysts cover HLN with a consensus score of 3.9/5. Average price target: $12.
What does Haleon plc do?Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various...
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.